Alfa Laval is substantially reinforcing its pharma workforce and committing a significant additional investment into R&D and operations over the next four years, it states.

“Secure supplies of safe and affordable medicine are needed now more than ever before. At Alfa Laval, we are committed to pioneering and empowering the pharmaceutical industry to push the boundaries of speed and scalability,” says Sammy Hulpiau, President Alfa Laval Food & Pharma Division.

The new structure has been designed to support pharmaceutical operators in tackling a range of challenges: optimizing the production of the rapidly increasing generic and biosimilar medicines while maximizing the patent window of patented medicines when a company benefits from a price premium, the company states. This comes on top of a pressing requirement to optimize productivity, sharpen competitiveness, secure compliance, mitigate risks, and build supply chain resilience.